

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE STATEMENT  
IN AN APPLICATION**
**LISTING OF REFERENCES**

 SEP 26 2007  
 September 24, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

2732.1047-010

APPLICATION NO.

10/526,175

FIRST NAMED INVENTOR

Gary R. Ostroff

371(c) DATE

July 29, 2005

EXAMINER

Pagonakis, Anna

CONFIRMATION NO.

6462

GROUP

1609

**U.S. PATENT DOCUMENTS**

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/A.P./	A1	3,903,297	09-02-1975	Robert
/A.P./	A2	4,237,266	12-02-1980	Sugiura, <i>et al.</i>
/A.P./	A3	4,492,540	01-08-1985	Yamamoto
/A.P./	A4	4,810,646	03-07-1989	Jamas, <i>et al.</i>
/A.P./	A5	4,992,540	02-12-1991	Jamas, <i>et al.</i>
/A.P./	A6	5,037,972	08-06-1991	Jamas, <i>et al.</i>
/A.P./	A7	5,082,936	01-21-1992	Jamas, <i>et al.</i>
/A.P./	A8	5,223,409	06-29-1993	Ladner, <i>et al.</i>
/A.P./	A9	5,223,491	06-29-1993	Donzis
/A.P./	A10	5,250,436	10-05-1993	Jamas, <i>et al.</i>
/A.P./	A11	5,506,124	04-09-1996	Jamas, <i>et al.</i>
/A.P./	A12	5,576,015	11-19-1996	Donzis
/A.P./	A13	5,702,719	12-30-1997	Donzis
/A.P./	A14	5,766,571	06-16-1998	Ceriani, <i>et al.</i>
/A.P./	A15	4,810,646	03-07-1989	Jamas, <i>et al.</i>
/A.P./	A16	4,761,402	08-02-1988	Williams, <i>et al.</i>
/A.P./	A17	4,739,046	04-19-1988	DiLuzio, <i>et al.</i>
/A.P./	A18	4,138,479	02-06-1979	Truscheit, <i>et al.</i>
/A.P./	A19	4,707,471	11-17-1987	Larm, <i>et al.</i>
/A.P./	A20	5,032,401	07-16-1991	Jamas, <i>et al.</i>

EXAMINER

/Anna Pagonakis/

DATE CONSIDERED

11/26/2007

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES</b>  <b>September 24, 2007</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6462	GROUP 1609

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/A.P./	A21	5,057,503	10-15-1991	Czop, <i>et al.</i>
/A.P./	A22	5,322,841	11-02-1992	Jamas, <i>et al.</i>
/A.P./	A23	5,320,849	06-14-1994	Hagiwara, <i>et al.</i>
/A.P./	A24	5,488,040	01-30-1996	Jamas, <i>et al.</i>
/A.P./	A25	5,532,223	07-02-1996	Jamas, <i>et al.</i>
/A.P./	A26	5,622,939	04-22-1997	Jamas, <i>et al.</i>
/A.P./	A27	3,943,247	03-09-1976	Komatsu, <i>et al.</i>
/A.P./	A28	5,504,079	04-02-1996	Jamas, <i>et al.</i>
/A.P./	A29	5,401,647	03-28-1995	Tanaka, <i>et al.</i>
/A.P./	A30	5,783,569	07-21-1998	Jamas, <i>et al.</i>
/A.P./	A31	5,817,643	10-06-1998	Jamas, <i>et al.</i>
/A.P./	A32	4,975,421	12-04-1990	Williams, <i>et al.</i>
/A.P./	A33	5,474,984	12-12-1995	Tanaka, <i>et al.</i>
/A.P./	A34	4,946,450	08-07-1990	Erwin
/A.P./	A35	5,663,324	09-02-1997	Jamas, <i>et al.</i>
/A.P./	A36	5,633,369	05-27-1997	Jamas, <i>et al.</i>
/A.P./	A37	5,811,542	09-22-1998	Jamas, <i>et al.</i>
/A.P./	A38	5,849,720	12-15-1998	Jamas, <i>et al.</i>
/A.P./	A39	5,607,677	03-04-1997	Jamas, <i>et al.</i>
/A.P./	A40	5,741,495	04-21-1998	Jamas, <i>et al.</i>

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 1/26/2007
---------------------------	---------------------------

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES</b>  <b>September 24, 2007</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	NO
/A.P./	B1	WO 02/058711 A1	08-01-2002	Sloan-Kettering Institute for Cancer Research		
/A.P./	B2	WO 2004/030613 A2	04-15-2004	University of Louisville Research Foundation, Inc.		
/A.P./	B3	WO 2006/085895 A2	08-17-2006	Biopolymer Engineering, Inc., <i>et al.</i>		

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	----------------------------

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>September 24, 2007</b> (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
	FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6462	GROUP 1609	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
/A.P./	C1	Cheung, N-K. V., et al., "Oral (1→3), (1→4)-β-D-Glucan Synergizes with Antiangiogenic GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma," <i>Clinical Cancer Research</i> , 8: 1217-1223 (May 2002).
/A.P./	C2	Bohn, J.A., et al., "(1→3)-β-D-Glucans as Biological Response Modifiers: A Review of Structure-Functional Activity Relationships," <i>Carbohydrate Polymers</i> , 28: 3-14 (1995).
/A.P./	C3	Yan, J., et al., "β-Glucan, A 'Specific' Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," <i>Journal of Immunology</i> , 163(6): 3045-3052 (1999).
/A.P./	C4	Wang, S-C., et al., "Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients," <i>Seminars in Oncology</i> , 28(6): 21-29 (2001).
/A.P./	C5	Ross, G.D., et al., "Therapeutic Intervention with Complement and β-Glucan in Cancer," <i>Immunopharmacology</i> , 42(1-3): 61-74 (1999).
/A.P./	C6	Database HCAPLUS on STN (Columbus, OH, USA), No. 137:119657, Cheung, N., "Antitumor Antibody-Enhancing Glucan," WO2002058711A1, 01 August 2002, abstract, see entire abstract.
/A.P./	C7	Database DRUGU on STN (Columbus, OH, USA), AN 1998:11655, Coiffier, B., et al., "A Multicenter, Randomized Phase II Study of Rituximab (Chimeric Anti-CD20 mAb) at Two Dosages in Patients with Relapsed or Refractory Intermediate or High-Grade NHL (IHH-NHL) or in Elderly Patients in First-Line Therapy," <i>Blood</i> (90, No. 10, Suppl. 1 Pt 1), 510A, 1997, abstract, see entire abstract.
/A.P./	C8	Database DRUGU on STN (Columbus, OH, USA), AN 1990-03601, Srivastava, R., et al., "Bioactive Polysaccharides from Plants," <i>Phytochemistry</i> , Vol. 28, No. 11, pages 2877-2883, 1989, abstract, see entire abstract.
/A.P./	C9	Borchers, A.T., et al., "MINIREVIEW: Mushrooms, Tumors, and Immunity," <i>Mushrooms and Immunity</i> , 221(4): 281-293 (1999).
/A.P./	C10	Sveinbjornsson, et al., "Macrophage Cytotoxicity Against Murine Meth A Sarcoma Involves Nitric Oxide-Mediated Apoptosis," <i>Biochem. Biophys. Res. Commun.</i> , 223(3): 643-649 (1996).
/A.P./	C11	Xia, Y., et al., "The γ-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells," <i>J. Immunol.</i> , 162: 2281-2290 (1999).
/A.P./	C12	Thornton, B.P., et al., "Analysis of the Sugar Specificity and Molecular Location of the γ-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/CD18)," <i>J. Immunol.</i> , 156: 1235-1246 (1996).
/A.P./	C13	Ross, G.D., et al., "Membrane Complement Receptor Type Three (CR3) has Lectin-Like Properties Analogous to Bovine Conglutinin and Functions as a Receptor for Zymosan and Rabbit Erythrocytes as well as a Receptor for iC3b," <i>The Journal of Immunology</i> , 134(5): 3307-3315 (1985).
/A.P./	C14	Ross, G.D., et al., "Specificity of Membrane Complement Receptor Type Three (CR3) for β-Glucans," <i>Complement</i> , 4: 61-74 (1987).
/A.P./	C15	Cain, J.A., et al., "Role of Complement Receptor Type Three and Serum Opsonins in the Neutrophil Response to Yeast," <i>Complement</i> , 4: 75-86 (1987).
/A.P./	C16	Suzuki, I., et al., "Inhibition of Experimental Pulmonary Metastasis of Lewis Carcinoma by Orally Administered β-Glucan in Mice," <i>Chem. Pharm. Bull.</i> , 39(6): 1606-1608 (1991).
/A.P./	C17	Roubey, et al., "Staurosporine Inhibits Neutrophil Phagocytosis but not iC3b Binding Mediated by CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 146(10): 3557-3562 (1991).

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	-------------------------------

Substitute for form 1449B/P/TO		ATTORNEY DOCKET NO. 2732.1047-010		APPLICATION NO. 10/526,175	
<b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>September 24, 2007</b>  (Use several sheets if necessary)		FIRST NAMED INVENTOR Gary R. Ostroff		371(c) DATE July 29, 2005	
		EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6462	
				GROUP 1609	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/A.P./	C18	Ross, G.D., <i>et al.</i> , "CR3 (CD11b, CD18): A Phagocyte and NK Cell Membrane Receptor with Multiple Ligand Specificities and Functions," <i>Clin Exp Immunol</i> , 92: 181-184 (1993).
/A.P./	C19	Muto, Satoshi, <i>et al.</i> , "CR3 (CD11b/CD18) Expressed by Cytotoxic T Cells and Natural Killer Cells is Upregulated in a Manner Similar to Neutrophil CR3 Following Stimulation with Various Activating Agents," <i>Journal of Clinical Immunology</i> , 13(3): 175-184 (1993).
/A.P./	C20	Vetvicka, V., <i>et al.</i> , "Soluble $\gamma$ -Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells," <i>J. Clin. Invest.</i> , 98(1): 50-61 (1996).
/A.P./	C21	Vetvicka, V., <i>et al.</i> , "Targeting of Natural Killer Cells to Mammary Carcinoma via Naturally Occurring Tumor Cell-Bound iC3b and beta-glucan-primed CR3 (CD11b/CD18)," <i>J. Immunol</i> , 159(2): 599-605 (1997).
/A.P./	C22	Reddy, R.K., <i>et al.</i> , "A Mixed Population of Immature and Mature Leucocytes in Umbilical Cord Blood Results in a Reduced Expression and Function of CR3 (CD11b/CD18)," <i>Clin Exp Immunol</i> , 114: 462-467 (1998).
/A.P./	C23	Xia, Y., <i>et al.</i> , "Generation of Recombinant Fragments of CD11b Expressing the Functional $\gamma$ -Glucan-Binding Lectin Site of CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 162(12): 7285-7293 (1999).
/A.P./	C24	Vetvicka, V., <i>et al.</i> , "Regulation of CR3 (CD11b/CD18)-dependent Natural Killer (NK) Cell Cytotoxicity by Tumour Target Cell MHC Class I Molecules," <i>Clin Exp Immunol</i> , 115: 229-235 (1999).
/A.P./	C25	Yan, J., <i>et al.</i> , "Critical Role of Kupffer Cell CR3 (CD11b/CD18) in the Clearance of IgM-Opsonized Erythrocytes or Soluble $\gamma$ -Glucan," <i>Immunopharmacology</i> , 46: 39-54 (2000).
/A.P./	C26	Ross, G.D., "Regulation of the Adhesion Versus Cytotoxic Functions of the Mac-1/CR3/ $\gamma$ <sub>M2</sub> Integrin Glycoprotein," <i>Critical Reviews in Immunology</i> , 20:197-222 (2000).
/A.P./	C27	Ross, G.D., "Role of the Lectin Domain of Mac-1/CR3 (CD11b/CD18) in Regulating Intercellular Adhesion," <i>Immunologic Research</i> , 25(3): 219-227 (2002).
/A.P./	C28	Biopolymer Engineering Presentation: Pioneering Carbohydrate Technology to Improve Human Health, April 2003.
/A.P./	C29	Blakeslee, Dennis, "The Two Faces of Immunity: Th1 and Th2," JAMA HIV/AIDS Resource Center, The Journal of the American Medical Association, <a href="http://www.ama-assn.org/special/hiv/newsline/briefing/th1.htm">http://www.ama-assn.org/special/hiv/newsline/briefing/th1.htm</a> (8/12/2002).
/A.P./	C30	"What's the Difference of Th1 Cells and Th2 Cells Effect?" <a href="http://www.madsci.org/posts/archives/may99/926272023.lm.r.html">http://www.madsci.org/posts/archives/may99/926272023.lm.r.html</a> (May 8, 1999).
/A.P./	C31	Heron Herbs: Feature Articles: "Balancing Cellular and Humoral Immunity," <a href="http://www.healthcalls.net/hh_art1alt.html">http://www.healthcalls.net/hh_art1alt.html</a> (8/16/2002).

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 11/26/2007
------------------------------	-------------------------------